{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:19:42Z","timestamp":1791299982277,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.pnpbp.2010.10.021","type":"journal-article","created":{"date-parts":[[2010,11,1]],"date-time":"2010-11-01T08:14:19Z","timestamp":1288599259000},"page":"161-168","source":"Crossref","is-referenced-by-count":35,"title":["An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia"],"prefix":"10.1016","volume":"35","author":[{"given":"Hidenobu","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Gen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pnpbp.2010.10.021_bb0005","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.pnpbp.2005.10.015","article-title":"Perospirone in the treatment of schizophrenia: Effect on verbal memory organization","volume":"30","author":"Araki","year":"2006","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0010","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1017\/S0033291703008900","article-title":"Medications and verbal memory impairment in schizophrenia: the role of anticholinergic drugs","volume":"34","author":"Brebion","year":"2004","journal-title":"Psycho Med"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0015","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0920-9964(00)00112-2","article-title":"Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: A longitudiral study","volume":"48","author":"Cuesta","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1192\/bjp.bp.108.055137","article-title":"Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis","volume":"194","author":"Cuesta","year":"2009","journal-title":"Br J Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2010.10.021_bb0025","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/WNF.0b013e3181572781","article-title":"Neurocognitive effects of ziprasidone and related fuctors in patients with chronic schizophrenia","volume":"31","author":"Gibel","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0030","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/oxfordjournals.schbul.a033373","article-title":"Intervention for neurocognitive deficits: Editor`s introduction","volume":"25","author":"Green","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0035","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s00213-002-1342-5","article-title":"Change in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study","volume":"169","author":"Harvey","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0040","series-title":"Wisconsin Card Sorting Test manual: revised and expanded. Psychological Assessment Resourses Oclessa","author":"Heaton","year":"1993"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0045","first-page":"249","article-title":"Dose equivalence of Psychotropic Drugs. Part X VII: Dose Equivalence of Novel Antipsychotics: Aripiprazole","volume":"9","author":"Inagaki","year":"2006","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0050","series-title":"Dose equivalence of psychotropic drugs","first-page":"11","article-title":"Dose equivalence of neuroleptics","author":"Inagaki","year":"1999"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0055","first-page":"295","article-title":"Clinical evaluation of aripiprazole in schizophrenic patients\u2013A comparative double-blind study with haloperidol","volume":"9","author":"Ishigooka","year":"2006","journal-title":"Jpn J Clin phychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0060","first-page":"323","article-title":"Cognitive impairment and antipsychotic medication in schizophrenia","volume":"2","author":"Iwanami","year":"1999","journal-title":"Jpn J Clin phychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0065","first-page":"1147","article-title":"Cognitive dysfunction in schizophrenia\u2013clinical implications and treatment","volume":"10","author":"Iyo","year":"2007","journal-title":"Jpn J Clin phychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0070","first-page":"243","article-title":"Atypical antipsychotics drugs and cognitive deficits in schizophrenia: A review of double-blind randomized trials","volume":"10","author":"Janier","year":"2003","journal-title":"Int Med J"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s002130050277","article-title":"The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study","volume":"131","author":"Kapur","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0080","first-page":"140","article-title":"Switching to perospirone improves verbal memory organization in schizophrenia","volume":"36","author":"Kasai","year":"2004","journal-title":"Ann Rep Mitsubishi Pharma Res Found"},{"issue":"2","key":"10.1016\/j.pnpbp.2010.10.021_bb0085","first-page":"205","article-title":"Tests for executive function","volume":"13","author":"Kashima","year":"2002","journal-title":"Jpn Psychiatry diagnostic"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0090","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1017\/S1461145703003651","article-title":"Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia","volume":"6","author":"Kasper","year":"2003","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0095","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/oxfordjournals.schbul.a033374","article-title":"The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis","volume":"25","author":"Keefe","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0100","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/ajp.2007.164.7.1061","article-title":"Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison","volume":"164","author":"Keefe","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0105","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00213-006-0428-x","article-title":"The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine","volume":"187","author":"Kern","year":"2006","journal-title":"Psychopharmacology(Berl)"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0110","first-page":"447","article-title":"Aripiprazole in treatment of schizophrenia: four case reports","volume":"10","author":"Kikuyama","year":"2007","journal-title":"Jpn J Clin phychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0115","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpsyc.1991.01810320063009","article-title":"Optimal dose of neuroleptic in acute schizophrenia: A controlled study of the neurileptic threshold and higher haloperidol dose","volume":"48","author":"McEvoy","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0120","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","article-title":"The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia","volume":"25","author":"Meltzer","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0125","doi-asserted-by":"crossref","first-page":"13591","DOI":"10.1073\/pnas.96.24.13591","article-title":"Cognition, schizophrenia, and the atypical antipsychotics drugs","volume":"96","author":"Meltzer","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0135","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.pnpbp.2004.01.019","article-title":"Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia","volume":"28","author":"Mori","year":"2004","journal-title":"Progr Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0140","first-page":"159","article-title":"Clinical evaluation of a new antipsychotic, perospirone Hcl, on schizophrenia: a comparative double-blind study with haloperidol","volume":"24","author":"Murasaki","year":"1997","journal-title":"Jpn Clin Eval"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0145","first-page":"1177","article-title":"Cognitive deficits induced by psychotropic drugs","volume":"10","author":"Nagata","year":"2007","journal-title":"Jpn J Clin phychopharmacol"},{"issue":"7","key":"10.1016\/j.pnpbp.2010.10.021_bb0150","first-page":"837","article-title":"Preparing a computerized memory test for aiding in the early diagnosis of mild Alzheimer's type dementia, and investigating the clinical usefulness thereof","volume":"10","author":"Onodera","year":"1999","journal-title":"Jpn J Geriatric Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0155","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol","volume":"57","author":"Purdon","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2010.10.021_bb0160","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00406-007-0748-9","article-title":"Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an active episode of schizophrenia","volume":"257","author":"Riedel","year":"2007","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0165","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1055\/s-0029-1239539","article-title":"Effect of aripiprazole on cognition in the treatment of patients with schizophrenia","volume":"43","author":"Riedel","year":"2010","journal-title":"Pharmacopsychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2010.10.021_bb0170","first-page":"201","article-title":"The efficacy of the long term use of donepezil HCL for cognitive impairment in patients with mild Alzheimer's dementia","volume":"15","author":"Sugiyama","year":"2004","journal-title":"Jpn J Geriatric Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2010.10.021_bb0175","first-page":"203","article-title":"The Brief Psychiatric Rating Scale (BPRS) its revised versions, subscales, reliability and validity","volume":"6","author":"Sumiyama","year":"1995","journal-title":"Jpn Psychiatry diagnostic"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0180","first-page":"739","article-title":"Comparison of clinical symptoms and cognitive function before and after risperidone switching in schizophrenia patients","volume":"8","author":"Suzuki","year":"2005","journal-title":"Jpn J Clin phychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0185","first-page":"1689","article-title":"Aripiprazole versus other antipsychotics: Comparative trial and switching study","volume":"10","author":"Takahashi","year":"2007","journal-title":"Jpn J Clin phychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0190","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"Suppl10","key":"10.1016\/j.pnpbp.2010.10.021_bb0195","first-page":"63","article-title":"Switching antipsychotic medications","volume":"58","author":"Weiden","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0200","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0205","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/oxfordjournals.schbul.a033379","article-title":"The effects of neurocognitive remedication on executive processing in patients with schizophrenia","volume":"25","author":"Wykes","year":"1999","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.10.021_bb0210","first-page":"1185","article-title":"The effects of second generation antipsychotic agents on cognitive dysfunction","volume":"10","author":"Yamamoto","year":"2007","journal-title":"Jpn J Clin phychopharmacol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610004070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610004070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,7]],"date-time":"2018-12-07T03:26:17Z","timestamp":1544153177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584610004070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0278584610004070"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2010.10.021","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}